Sangamo BioSciences Announces Presentation of Phase 2 Data in ALS

Sangamo reported promising Phase II results for their first-in-class ALS therapeutic, SB-509, a zinc finger protein transcriptional activator of the VEGF-A gene. Intramuscular injection of SB-509 was shown to delay deterioration in muscle strength in ALS patients. Sangamo is carefully analyzing the trial data to better inform future trial design in preparation for a follow-on trial.

Click here to read more.

Share this: